PGNY

Progyny Inc (PGNY) | Rumor.io

Progyny

PGNY

Attention (50-day avg)0%

Attention rank (50-day avg)#3,960

Bullish sentiment (50-day avg)67%

Price to earnings ratio27.8

Market capitalization2B

Earnings per share0.92

Dividend yield (TTM)—

Revenue (annual)1.3B

Net income (annual)58.5M

Social

What share of all stock conversation is about PGNY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 13

Keybanc analyst Scott Schoenhaus maintains a Buy rating on Progyny with a price target of $35.00.
Progyny is experiencing a short-term pullback, trading lower today, down -1.35%.
The stock is showing signs of weakness in intraday action, retracting gains after recent moves.

Generated by AI

Sentiment

Of the messages about PGNY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	89.53% +2.26
Bearish	—	—	—	10.47% -2.26

Bullish· May 8

$PGNY continues to look like one of the strongest names in healthcare benefits growth, with a strong Q1 beat and raised guidance reinforcing its leadership position in fertility and women’s health benefits.
$PGNY has delivered a massive surge, soaring by 17.38% and closing at $22.49, a gain of a full $3.33, driven by strong profits and momentum in the fertility benefits and women’s health tech space.
$PGNY's Q1 2026 profits shocked everyone, beating expectations by 63.99%, but executives are dodging basic questions about future sales, suggesting a potentially strong future for the company.

Bearish· Sep 19

Progyny's service offering is no longer differentiated, as others have copied its model, making it a matter of time before the company lost market share.
The loss of a client accounting for 12% of revenue is a significant blow, with the company now trading at a high multiple of 27 times earnings, despite expectations of sales growth.
The stock's 30% decline is a massive overreaction, with some analysts calling the selloff excessive, but the company's valuation may need to come down to the $14 range to find support.

Generated by AI

Topics

Of the messages about PGNY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	73.25%
Technical Analysis	—	—	0%	3.31%
Analysts	—	—	0%	11.66%
Earnings	—	—	0%	4.79%
Controversies	—	—	0%	0%
Macro	—	—	0%	6.99%

Oct 16

Progyny ($PGNY) shares jumped up to 11.5% on reports of a White House proposal to expand access to IVF and encourage employers to offer IVF and infertility benefits.
The proposal, announced by President Trump, aims to make IVF more accessible and reduce fertility treatment costs through a voluntary program that expands workplace coverage options.
The Labor Department will issue guidance after the announcement, which is expected to benefit companies like Progyny that provide IVF services.

Generated by AI

Community

Of the messages about PGNY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	38.38%
Newcomers	—	—	100%	61.62%

Regulars· Sep 19

The company's service offering is no longer differentiated, as it has been copied by others, which was a matter of time given its lack of a moat.
The company has lost a significant client, accounting for 12% of revenue, which has led to a 30% decline in stock price despite still having expectations to deliver sales/member growth.
The loss of the client is concerning, but not yet thesis-breaking, and the company's valuation is now 27x earnings, with some analysts downgrading their price targets and rating the stock as "Buy" or "Overweight".

Newcomers· May 8

$PGNY's strong Q1 performance and raised guidance reinforce its leadership position in fertility and women's health benefits.
The company's growth in healthcare benefits is a key factor in its strong performance.
Progyny's leadership position in fertility and women's health benefits is a key driver of its growth and success.

Generated by AI

Progyny has delivered a mixed ride for shareholders, with the stock climbing over the past year but still showing a steep decline over five years. This puts a sharper spotlight on what investors are really paying for its earnings today. With that backdrop, the key issue is whether the current share price around US$27 fairly reflects the company’s profit engine. Over the past 5 years, Progyny’s share price has fallen 57.5%, which raises the question of whether the market is reassessing how...

11d agoYahoo Finance

Progyny: Best-In-Class And Likely To Exceed Analyst Estimates In 2027 (NASDAQ:PGNY)

12d agoSeeking Alpha

Options Movement At Progyny: KEVIN GORDON Exercises Worth $325K

14d agoBenzinga

Progyny director Kevin Gordon sells $321,358 in company stock

15d agoInvesting.com

Progyny Insider Sold Shares Worth $321,358, According to a Recent SEC Filing

Kevin K Gordon, Director, on September 10, 2026, sold 11,500 shares in Progyny (PGNY) for $321,358.

16d agoYahoo Finance

Also Discussed

Investors talking about PGNY also mention

#	Name	Attention
1	InMode Ltd.INMD	0%0
2	Arrowhead Pharmaceuticals, Inc.ARWR	0%+0
3	Azenta, Inc.AZTA	0%0
4	Teladoc Health Inc.TDOC	0%+0
5	Fomento Economico Mexicano S.A.B. de C.V. ADRFMX	0%0
6	Sea Limited Sponsored ADRSE	0%0
7	Surgery Partners Inc.SGRY	0%0
8	Fastly, Inc.FSLY	0.01%0
9	SWAV - ShockWave Medical, Inc.	——
10	Evolent Health IncEVH	0%0

Progyny Inc

Healthcare
Healthcare Plans

Progyny Inc is a healthcare benefits management company that provides fertility, family-building, and women’s health solutions for employers. Progyny designs integrated benefit programs that combine clinical expertise, personalized member support, selective provider networks, and pharmacy benefits to help organizations offer specialized reproductive and lifecycle care. Its services support areas such as fertility treatment, pregnancy and postpartum care, menopause and midlife support, and benefit navigation for adoption and surrogacy reimbursement. Progyny serves employers across multiple industries that want to include comprehensive family-building and women’s health coverage in their employee benefits packages. The company operates as a focused specialist in employer-sponsored healthcare benefits, playing a distinct role in making complex care pathways easier to manage for members, providers, and benefits administrators.

Website

Location

1359 Broadway

New York, NY, 10018

United States

Social

What share of all stock conversation is about PGNY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 13

Keybanc analyst Scott Schoenhaus maintains a Buy rating on Progyny with a price target of $35.00.
Progyny is experiencing a short-term pullback, trading lower today, down -1.35%.
The stock is showing signs of weakness in intraday action, retracting gains after recent moves.

Generated by AI

Sentiment

Of the messages about PGNY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	89.53% +2.26
Bearish	—	—	—	10.47% -2.26

Bullish· May 8

$PGNY continues to look like one of the strongest names in healthcare benefits growth, with a strong Q1 beat and raised guidance reinforcing its leadership position in fertility and women’s health benefits.
$PGNY has delivered a massive surge, soaring by 17.38% and closing at $22.49, a gain of a full $3.33, driven by strong profits and momentum in the fertility benefits and women’s health tech space.
$PGNY's Q1 2026 profits shocked everyone, beating expectations by 63.99%, but executives are dodging basic questions about future sales, suggesting a potentially strong future for the company.

Bearish· Sep 19

Progyny's service offering is no longer differentiated, as others have copied its model, making it a matter of time before the company lost market share.
The loss of a client accounting for 12% of revenue is a significant blow, with the company now trading at a high multiple of 27 times earnings, despite expectations of sales growth.
The stock's 30% decline is a massive overreaction, with some analysts calling the selloff excessive, but the company's valuation may need to come down to the $14 range to find support.

Generated by AI

Topics

Of the messages about PGNY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	73.25%
Technical Analysis	—	—	0%	3.31%
Analysts	—	—	0%	11.66%
Earnings	—	—	0%	4.79%
Controversies	—	—	0%	0%
Macro	—	—	0%	6.99%

Oct 16

Progyny ($PGNY) shares jumped up to 11.5% on reports of a White House proposal to expand access to IVF and encourage employers to offer IVF and infertility benefits.
The proposal, announced by President Trump, aims to make IVF more accessible and reduce fertility treatment costs through a voluntary program that expands workplace coverage options.
The Labor Department will issue guidance after the announcement, which is expected to benefit companies like Progyny that provide IVF services.

Generated by AI

Community

Of the messages about PGNY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	38.38%
Newcomers	—	—	100%	61.62%

Regulars· Sep 19

The company's service offering is no longer differentiated, as it has been copied by others, which was a matter of time given its lack of a moat.
The company has lost a significant client, accounting for 12% of revenue, which has led to a 30% decline in stock price despite still having expectations to deliver sales/member growth.
The loss of the client is concerning, but not yet thesis-breaking, and the company's valuation is now 27x earnings, with some analysts downgrading their price targets and rating the stock as "Buy" or "Overweight".

Newcomers· May 8

$PGNY's strong Q1 performance and raised guidance reinforce its leadership position in fertility and women's health benefits.
The company's growth in healthcare benefits is a key factor in its strong performance.
Progyny's leadership position in fertility and women's health benefits is a key driver of its growth and success.

Generated by AI

Progyny

Social

Jul 13

Sentiment

Bullish· May 8

Bearish· Sep 19

Topics

Oct 16

Community

Regulars· Sep 19

Newcomers· May 8

News

Progyny director Kevin Gordon sells $311,858 in shares

Progyny (PGNY) Stock Looks Fairly Valued Despite Its 57% Five Year Slide

Progyny: Best-In-Class And Likely To Exceed Analyst Estimates In 2027 (NASDAQ:PGNY)

Options Movement At Progyny: KEVIN GORDON Exercises Worth $325K

Progyny director Kevin Gordon sells $321,358 in company stock

Progyny Insider Sold Shares Worth $321,358, According to a Recent SEC Filing

Also Discussed

Progyny Inc

Company Information

Location

News

Progyny director Kevin Gordon sells $311,858 in shares

Progyny (PGNY) Stock Looks Fairly Valued Despite Its 57% Five Year Slide

Progyny: Best-In-Class And Likely To Exceed Analyst Estimates In 2027 (NASDAQ:PGNY)

Options Movement At Progyny: KEVIN GORDON Exercises Worth $325K

Progyny director Kevin Gordon sells $321,358 in company stock

Progyny Insider Sold Shares Worth $321,358, According to a Recent SEC Filing

Also Discussed

Social

Jul 13

Sentiment

Bullish· May 8

Bearish· Sep 19

Topics

Oct 16

Community

Regulars· Sep 19

Newcomers· May 8